NewAmsterdam Pharma Co N.V.
For the period ended Jun 4, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 4, 2025 · Filed May 8, 2025
Contents
Pay Versus Performance
In accordance with rules adopted by the SEC pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, we provide the following disclosure regarding the relationship between Company performance and the “compensation actually paid” to our principal executive officer (“PEO”) and other NEOs (the “Non-PEO NEOs”) for the fiscal years listed below. The Compensation Committee did not consider the pay versus performance disclosure below in making its pay decisions for any of the years shown.
| Year · SummaryCompensationTable Totalfor PEO1($) · CompensationActually Paidto PEO1, 2($) · AverageSummaryCompensationTable Totalfor Non-PEONEOs1($) · AverageCompensationActually PaidtoNon-PEONEOs1,2($) · Value of InitialFixed $100Investment basedon:3 · NetIncome($ Millions) | |||||||
|---|---|---|---|---|---|---|---|
| TSR($) · PeerGroupTSR($) | |||||||
| 2024 | 6,469,297 | 49,549,373 | 2,588,362 | 13,170,066 | 235.78 | 104.00 | (242) |
| 2023 | 5,805,558 | 4,717,541 | 3,265,820 | 3,318,816 | 102.48 | 104.59 | (177) |
| 1. | Michael Davidson, M.D. was our PEO for each year presented. The individuals comprising the Non-PEO NEOs for each year presented are listed below. |
| 2023 | 2024 |
| Ian Somaiya | Ian Somaiya |
| John Kastelein, M.D., Ph.D. FESC | John Kastelein, M.D., Ph.D. FESC |
| Juliette Audet | |
| Douglas Kling |
| 2. | Calculated in accordance with Item 402(v) of Regulation S-K and does not reflect compensation realized by the Company’s NEOs in either of the years presented. Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO NEOs from the Summary Compensation Table as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. |
| Year | SummaryCompensationTable Total forPEO($) | Exclusion ofStock Awardsfor PEO($) | Inclusion ofEquity Valuesfor PEO($) | CompensationActually Paid toPEO($) |
|---|---|---|---|---|
| 2024 | 6,469,297 | (5,347,060) | 48,427,136 | 49,549,373 |
| 2023 | 5,805,558 | (4,923,558) | 3,835,541 | 4,717,541 |
| Year | AverageSummaryCompensationTable Total forNon-PEO NEOs($) | AverageExclusion ofStock Awardsfor Non-PEONEOs($) | AverageInclusion ofEquity Valuesfor Non-PEONEOs($) | AverageCompensationActually Paidto Non-PEONEOs($) |
|---|---|---|---|---|
| 2024 | 2,588,362 | (1,812,416) | 12,394,121 | 13,170,066 |
| 2023 | 3,265,820 | (2,861,653) | 2,914,648 | 3,318,816 |
Amounts in the columns entitled “Exclusion of Stock Awards for PEO” and “Average Exclusion of Stock Awards for Non-PEO NEOs” are the totals from the “Option Awards” column of the Summary Compensation Table. Amounts in the columns entitled “Inclusion of Equity Values for PEO” and “Average Inclusion of Equity Values for Non-PEO NEOs” in the tables above were calculated as follows:
| Year | Year-EndFair Value ofOutstandingand UnvestedEquityAwardsGrantedDuring Yearfor PEO($) | Year-over-Year Changein Fair ValueofOutstandingand UnvestedEquityAwardsGranted inPrior Yearsfor PEO($) | Vesting-DateFair Value ofEquityAwardsGranted andVestedDuring Yearfor PEO($) | Year-over-Year Changein Fair Valueof UnvestedEquityAwardsGranted inPrior Yearthat VestedDuring Yearfor PEO($) | Year-EndFair Value ofEquityAwards thatFailed toMeet VestingConditionsDuring Yearfor PEO($) | Value ofDividends orOtherEarningsPaid onEquityAwards NotOtherwiseReflected forPEO($) | Total EquityAwardAdjustmentsfor PEO($) |
|---|---|---|---|---|---|---|---|
| 2024 | 18,036,059 | 22,714,096 | — | 7,676,981 | — | — | 48,427,136 |
| 2023 | 4,060,090 | (403,427) | — | 178,878 | — | — | 3,835,541 |
| Year | AverageYear-EndFair Value ofOutstandingand UnvestedEquityAwardsGrantedDuring Yearr for Non-PEO NEOs($) | AverageYear-over-year Changein Fair ValueofOutstandingand UnvestedEquityAwardsGranted inPrior Yearsfor Non-PEONEOs($) | AverageVesting-DateFair Value ofEquityAwardsGranted andVestedDuring Yearfor Non-PEONEOs($) | AverageYear-over-Year Changein Fair Valueof UnvestedEquityAwardsGranted inPrior Yearthat VestedDuring Yearfor Non-PEONEOs($) | AverageYear-EndFair Value ofEquityAwards thatFailed toMeet VestingConditionsDuring Yearfor Non-PEONEOs($) | AverageValue ofDividends orOtherEarningsPaid onEquityAwards NotOtherwiseReflected forNon-PEONEOs($) | TotalAverageEquityAwardAdjustmentsfor Non-PEONEOs ($) |
|---|---|---|---|---|---|---|---|
| 2024 | 4,683,173 | 6,005,580 | — | 1,705,368 | — | — | 12,394,121 |
| 2023 | 3,005,046 | (88,047) | — | (2,351) | — | — | 2,914,648 |
| 3. | The Peer Group Total Shareholder Return (“TSR”) set forth in this table utilizes the Nasdaq Biotechnology Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. The comparison assumes $100 was invested for the period starting December 31, 2022, through the end of the listed year in the Company and in the Nasdaq Biotechnology Index, respectively. Historical stock performance is not necessarily indicative of future stock performance. |
Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and TSR
The following chart sets forth the relationship between
Compensation
Actually Paid to our PEO, the average of Compensation Actually
Paid
to our Non-PEO NEOs, and the cumulative
TSR over
the two most recently completed fiscal years for the Company and the Nasdaq Biotechnology Index, our selected peer group.
Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Net Income
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our net income
during
the
two most
recently completed fiscal years.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.